Le Syndicat (FR)
{name}
{subtitle}
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
city
~68 mi. (Vandœuvre-lès-Nancy, France, +176 more cities)
facility
Institut De Cancerologie De Lorraine ( Site 2072)
condition
Endometrial Carcinoma, +1 more condition
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
city
~68 mi. (Vandœuvre-lès-Nancy, France, +140 more cities)
facility
C.H.U. de Nancy. Hopital de Brabois Adultes ( Site 0180)
condition
Hepatocellular Carcinoma
drug
lenvatinib, +2 more drugs
drug type
chemotherapy, +2 more types
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
city
~68 mi. (Vandœuvre-lès-Nancy, France, +45 more cities)
facility
Institut De Cancerologie De Lorraine ( Site 1010)
condition
Esophageal Squamous Cell Carcinoma
drug
cisplatin, +5 more drugs
drug type
chemotherapy, +2 more types
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
city
~68 mi. (Vandœuvre-lès-Nancy, France, +126 more cities)
facility
Institut De Cancerologie De Lorraine ( Site 0222)
condition
Adenocarcinoma of the Gastroesophageal Junction, +1 more condition
drug
FOLFOX regimen, +3 more drugs
drug type
chemotherapy, +2 more types
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
city
~68 mi. (Vandœuvre-lès-Nancy, France, +156 more cities)
facility
CHRU Nancy - Hôpitaux de Brabois /ID# 201076
biomarker
IGH-CCND1 Fusion, +1 more biomarker
condition
Multiple Myeloma
drug
dexamethasone, +1 more drug
drug type
chemotherapy, +1 more type
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
city
~68 mi. (Vandœuvre-lès-Nancy, France, +27 more cities)
facility
Institut De Cancerologie De Lorraine ( Site 1204)
condition
Clear Cell Renal Cell Carcinoma
drug
belzutifan, +4 more drugs
drug type
immunotherapy, +1 more type
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B)
city
~68 mi. (Vandœuvre-lès-Nancy, France, +28 more cities)
facility
Institut De Cancerologie De Lorraine ( Site 3204)
condition
Clear Cell Renal Cell Carcinoma
drug
belzutifan, +5 more drugs
drug type
immunotherapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~69 mi. (Nancy, France, +226 more cities)
facility
Centre D Oncologie de Gentilly ( Site 0432)
condition
Prostate Adenocarcinoma
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type